Streptococcal Inactivator in Human Chemoattractants

人类化学引诱剂中的链球菌灭活剂

• 批准号: 6800468
• 负责人: PAUL Patrick CLEARY
• 金额: $ 25.99万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-01 至 2006-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6800468
• 关键词: Streptococcal; Inactivator; Human; Chemoattractants

DESCRIPTION (provided by applicant): This project is an attempt to understand the mechanism by which group A streptococcus modulates host defenses. These streptococci have evolved proteins including the C5a peptidase that destroys C5a, an important early signal that attracts protective phagocytes to infected tissue. The recent discovery that the peptidase is also a fibronectin and cell-binding protein has become a significant new focus. Experiments are planned to evaluate the importance of these activities, relative to peptidase activity in virulence using intranasal and subdermal mouse models of infection. Recognition that penicillin often fails to eliminate group A streptococci from throats of ill children and the recent resurgence of serious complications associated with streptococcal infections, has prompted an intense effort to develop preventive vaccines by industry and NIH. The C5a peptidase is a major focus of vaccine development, increasing the need to learn more about its role in virulence, and its impact on host defenses. New data indicates that the C5a peptide required for successful colonization and persistence of streptococci in nasal associated lymphoid tissue.

描述(由申请人提供)：本项目试图了解A组链球菌调节宿主防御的机制。这些链球菌进化出了包括C5a多肽酶在内的蛋白质，C5a是一种重要的早期信号，可以吸引保护性吞噬细胞到感染组织中。最近发现的多肽酶也是一种纤维连接蛋白和细胞结合蛋白，这已经成为一个重要的新焦点。计划利用小鼠鼻腔和皮下感染模型，评估这些活性相对于多肽酶活性在毒力中的重要性。认识到青霉素往往不能消除患病儿童喉咙中的A组链球菌，以及最近与链球菌感染相关的严重并发症的卷土重来，促使工业界和美国国立卫生研究院大力开发预防性疫苗。C5a多肽酶是疫苗开发的一个主要焦点，增加了更多了解其在毒力中的作用及其对宿主防御的影响的必要性。新的数据表明，C5a肽是链球菌在鼻腔相关淋巴组织中成功定植和持续存在所必需的。